CERN-MEDICIS (Medical Isotopes Collected from ISOLDE): A New Facility

Ricardo Dos Santos Augusto; Leo Buehler; Zoe Lawson; Stefano Marzari; Monika Stachura; Thierry Stora; CERN-MEDICIS collaboration

doi:10.3390/app4020265

journal article Open Access May 16, 2014

CERN-MEDICIS (Medical Isotopes Collected from ISOLDE): A New Facility

Ricardo Dos Santos Augusto Leo Buehler Zoe Lawson Stefano Marzari Monika Stachura Thierry Stora

CERN-MEDICIS collaboration

Applied Sciences Vol. 4 No. 2 pp. 265-281 · MDPI AG

View at Publisher Save 10.3390/app4020265

Abstract

About 50% of the 1.4 GeV CERN (European Organization for Nuclear Research, www.cern.ch) protons are sent onto targets to produce radioactive beams by online mass separation at the Isotope Separator Online Device (ISOLDE) facility, for a wide range of studies in fundamental and applied physics. CERN-MEDICIS is a spin-off dedicated to R&D in life sciences and medical applications. It is located in an extension of the Class A building presently under construction. It will comprise laboratories to receive the irradiated targets from a new station located at the dump position behind the ISOLDE production targets. An increasing range of innovative isotopes will thus progressively become accessible from the start-up of the facility in 2015 onward; for fundamental studies in cancer research, for new imaging and therapy protocols in cell and animal models and for pre-clinical trials, possibly extended to specific early phase clinical studies up to Phase I trials. Five hundred megabecquerel isotope batches purified by electromagnetic mass separation combined with chemical methods will be collected on a weekly basis. A possible future upgrade with gigabecquerel pharmaceutical-grade i.e., current good manufacturing practices (cGMP) batch production capabilities is finally presented.

Topics

No keywords indexed for this article. Browse by subject →

References

37

[1]

Stora, T., Da Visitacao, S.F., Mathot, S., and Bowen, P. (2009). Nanostructured Target for Isotope Production. (20110235766 A1), U.S. Patent.

[2]

Mendonca, T.M., Hodak, R., Ghetta, V., Allibert, M., Heuer, D., Noah, E., Cimmino, S., Delonca, M., Gottberg, A., and Kronberger, M. (2014). Production and release of ISOL beams from molten fluoride salt targets. Nucl. Instrum. Methods Phys. Res. Sect. B, submitted for publication. 10.1016/j.nimb.2014.03.003

[3]

Albrow "The FLUKA code: Description and benchmarking" Proceedings of the Hadronic Shower Simulation Workshop AIP Conference (2007) 10.1063/1.2720455

[4]

Ferrari, A., Sala, P.R., Fassò, A., and Ranft, J. (2005). FLUKA: A Multi-Particle Transport Code, CERN. 10.2172/877507

[5]

Access to the Yield information. Available online:https://oraweb.cern.ch/pls/isolde/query_tgt.

[6]

Stora "Sergey Vaintraub, Pierre Delahaye, Hanna Franberg-Delahaye, Marie-Genevieve Saint-Laurent and Gerard Lhersonneau. A high intensity 6He beam for the β-beam neutrino oscillation facility" EPL (2012) 10.1209/0295-5075/98/32001

[7]

Morley "An automated module for the separation and purification of cyclotron-produced 99mTcO4" Nuclear Med. Biol. (2012) 10.1016/j.nucmedbio.2011.10.006

[8]

Beyer "Radioactive ion beams for biomedical research and nuclear medical application" Hyperfine Interact. (2000) 10.1023/a:1012670018533

[9]

Beyer "Spallation-produced thulium-167 for medical applications" Med. Radionucl. Imaging IAEA (1980)

[10]

Beyer "A new type of 81Rb-81mKr generator for medical use" J. Appl. Radiat. Isot. (1984) 10.1016/0020-708x(84)90015-2

[11]

Beyer, G.J., and Bergmann, R. (November, January 30). Workshop on Endoradionuclide Therapy, Dresden, Germany.

[12]

Beyer "The influence of EDTMP-concentration on the biodistribution of radio-lanthanides and 225-Ac in tumor-bearing mice" Nucl. Med. Biol. (1997) 10.1016/s0969-8051(97)80001-7

[13]

Proposal to the ISOLDE committee, CERN/ISC-4/P42 (ISOLDE experiment ISC330). Available online:https://cds.cern.ch/record/5299?ln=en.

[14]

Proposal to the ISOLDE committee, CERN/ISC93-14/ISC/P48 (ISOLDE experiment ISC331). Available online:https://cds.cern.ch/record/5298?ln=en.

[15]

Addendum to the proposal to the ISOLDE committee, CERN/ISC93-14/ISC/P48. Available online:http://cds.cern.ch/record/297279/.

[16]

Addendum 1 to ISOLDE experiments ISC330 and ISC331 from 4 May 1994. Available online:https://cds.cern.ch/record/294853/files/SC00000194.pdf.

[17]

Pochon "A novel derivative of the chelon desferrioxamine for site specific conjugation to antibodies" Int. J. Cancer (1989) 10.1002/ijc.2910430637

[18]

Beyer "Biokinetics of monoclonal antibodies labeled with radio-lanthanides and 225-Ac in xenografted nude mice: Preliminary results" J. Lab. Comp. Radiopharm. (1995)

[19]

Beyer "Comparison of the biokinetics of octreotide labeled with radio-lanthanides and 111In in tumor bearing rats" Eur. J. Nucl. Med. (1996)

[20]

Beyer "Is Tb-152 suitable to monitor tissue doses in alpha therapy with Tb-149 using PET?" Eur. J. Nucl. Med. (1998)

[21]

Beyer "Targeted alpha therapy in vivo: Direct evidence for single cancer cell kill using 149Tb-rituximab" Eur. J. Nucl. Med. Mol. Imaging (2004) 10.1007/s00259-003-1413-9

[22]

Proposal to the ISOLDE committe CERN/97-14/ISC/P-90 (ISOLDE experiment IS363). Available online:https://cds.cern.ch/record/491305?ln=en.

[23]

Addendum 1 to IS363 dated 31 January 2000. Available online:https://cds.cern.ch/record/430342?ln=en.

[24]

Beyer, G.J. (2005, January 10–12). Medical application of Radioactive ion beams. Presented at NuPEC, CERN, Geneva Switzerland.

[25]

Zhernosekov "A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β-Radionuclide Therapy: An in vivo proof-of-concept study with a new receptor-targeted folate derivative" J. Nucl. Med. (2012) 10.2967/jnumed.112.107540

[26]

Buchegger, F., Tourwe, D., Kosinski, M., Viertl, D., Stora, T., Buehler, L., Miralbell, R., and Prior, J. 68Ga-labeled NODAGA- and DOTA-neurotensin analogs for targeting breast, prostate and pancreas cancers. Available online:http://www.radiologiekongress.ch/cms/website.php?id=/de/attendees/program.htm.

[27]

Butz "A TDPAC-camera" Nucl. Instrum. Methods Phys. Res. Sect. A (1989) 10.1016/0168-9002(89)90311-2

[28]

Proposal to the ISOLDE committee CERN/ISC91-92/ISC/P20. Available online:https://cds.cern.ch/record/5746?ln=en.

[29]

Butz "199mHg-derivatives of ascorbate oxidase and laccase: Selective depletion and blocking of Cu-sites" Hyperfine Interact (1993) 10.1007/bf00567475

[30]

Lippert "Hg-coordination studies of cysteine containing oligopeptides" Z. Naturforsch. A (1996) 10.1515/zna-1996-5-617

[31]

Lippert "Small scale intramolecular flexibility in 111mCd-plastocyanin" Z. Naturforsch. A (1996) 10.1515/zna-1996-5-618

[32]

Ctortecka "Hg-coordination studies of oligopeptides containing cysteine, histidine and tyrosine by 199mHg-TDPAC" Hyperfine Interact. (1999) 10.1023/a:1017008631060

[33]

Soldner "Measurement and calculation of electric field gradients in Hg-mercaptides" Z. Naturforsch. A (1998) 10.1515/zna-1998-6-721

[34]

Iranzo "The application of 199Hg NMR and 199m Perturbed Angular Correlation (PAC) Spectroscopy to define the biological chemistry of Hg(II): A case study with designed two- and three-stranded coiled coils" Eur. J. Chem. (2007) 10.1002/chem.200701208

[35]

Design of a Three‐Helix Bundle Capable of Binding Heavy Metals in a Triscysteine Environment

Saumen Chakraborty, Joslyn Yudenfreund Kravitz, Peter W. Thulstrup et al.

Angewandte Chemie International Edition 2011 10.1002/anie.201006413

[36]

Luczkowski "Probing the coordination environment of the human copper chaperone HAH1: Characterization of Hg(II)-bridged homodimeric species in solution" Eur. J. Chem. (2013) 10.1002/chem.201204184

[37]

Gottberg, A., Stachura, M., Kowalska, M., Bissell, M.L., Arcisauskaite, V., Blaum, K., Helmke, A., Johnston, K., Kreim, K., and Larsen, F.H. (2014). Billion-fold sensitivity improvement in NMR spectroscopy of magnesium ions in solution. Angew. Chem., Unpublished work.

Cited By

82

Scandium thermal release from activated natTi and natV target materials in mixed particle fields: Investigation of parameters relevant for isotope mass separation

Edgars Mamis, Patrīcija Kalniņa · 2024

Nuclear Instruments and Methods in...

Production Cross-Section Measurements for Terbium Radionuclides of Medical Interest Produced in Tantalum Targets Irradiated by 0.3 to 1.7 GeV Protons and Corresponding Thick Target Yield Calculations

Charlotte Duchemin, Thomas E. Cocolios · 2021

Frontiers in Medicine

Chemical Purification of Terbium-155 from Pseudo-Isobaric Impurities in a Mass Separated Source Produced at CERN

Ben Webster, Peter Ivanov · 2019

Scientific Reports

Metrics

82

Citations

37

References

Details

Published: May 16, 2014
Vol/Issue: 4(2)
Pages: 265-281
License: View

Authors

R

Ricardo Dos Santos Augusto